Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Y3LJ
|
|||
| Former ID |
DCL000471
|
|||
| Drug Name |
AZD5904
|
|||
| Synonyms |
AZD5904; UNII-62A9CG81VN; 62A9CG81VN; AZD-5904; 3-[[(2R)-oxolan-2-yl]methyl]-2-sulfanylidene-7H-purin-6-one; 3-(((2R)-Oxolan-2-yl)methyl)-2-sulfanylidene-7H-purin-6-one; 2-Thioxanthine, TX4; SCHEMBL2288062; GTPL7728; TX-4; BDBM92469; AZD 5904; 618913-30-7; HY-111341; CS-0035112; 6H-Purin-6-one, 1,2,3,9-tetrahydro-3-(((2R)-tetrahydro-2-furanyl)methyl)-2-thioxo-; (R)-3-((Tetrahydrofuran-2-yl)methyl)-2-thioxo-1,2,3,7-tetrahydro-6H-purin-6-one; 6H-Purin-6-one, 1,2,3,7-tetrahydro-3-(((2R)-tetrahydro-2-furanyl)methyl)-2-thioxo-
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Chronic obstructive pulmonary disease [ICD-11: CA22; ICD-10: J44, J44.9] | Discontinued in Phase 1 | [1], [2] | |
| Multiple sclerosis [ICD-11: 8A40] | Discontinued in Phase 1 | [1], [2] | ||
| Company |
AstraZeneca
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C10H12N4O2S
|
|||
| Canonical SMILES |
C1CC(OC1)CN2C3=C(C(=O)NC2=S)NC=N3
|
|||
| InChI |
1S/C10H12N4O2S/c15-9-7-8(12-5-11-7)14(10(17)13-9)4-6-2-1-3-16-6/h5-6H,1-4H2,(H,11,12)(H,13,15,17)/t6-/m1/s1
|
|||
| InChIKey |
RSPDBEVKURKEII-ZCFIWIBFSA-N
|
|||
| CAS Number |
CAS 618913-30-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Myeloperoxidase (MPO) | Target Info | Inhibitor | [3] |
| KEGG Pathway | Phagosome | |||
| Transcriptional misregulation in cancer | ||||
| Pathway Interaction Database | C-MYB transcription factor network | |||
| IL23-mediated signaling events | ||||
| WikiPathways | Folate Metabolism | |||
| Vitamin B12 Metabolism | ||||
| Selenium Micronutrient Network | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7728). | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024670) | |||
| REF 3 | Clinical pipeline report, company report or official report of AstraZeneca (2009). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.